Literature DB >> 10328075

Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

T V Inglesby1, D A Henderson, J G Bartlett, M S Ascher, E Eitzen, A M Friedlander, J Hauer, J McDade, M T Osterholm, T O'Toole, G Parker, T M Perl, P K Russell, K Tonat.   

Abstract

OBJECTIVE: To develop consensus-based recommendations for measures to be taken by medical and public health professionals following the use of anthrax as a biological weapon against a civilian population. PARTICIPANTS: The working group included 21 representatives from staff of major academic medical centers and research, government, military, public health, and emergency management institutions and agencies. EVIDENCE: MEDLINE databases were searched from January 1966 to April 1998, using the Medical Subject Headings anthrax, Bacillus anthracis, biological weapon, biological terrorism, biological warfare, and biowarfare. Review of references identified by this search led to identification of relevant references published prior to 1966. In addition, participants identified other unpublished references and sources. CONSENSUS PROCESS: The first draft of the consensus statement was a synthesis of information obtained in the formal evidence-gathering process. Members of the working group provided formal written comments which were incorporated into the second draft of the statement. The working group reviewed the second draft on June 12, 1998. No significant disagreements existed and comments were incorporated into a third draft. The fourth and final statement incorporates all relevant evidence obtained by the literature search in conjunction with final consensus recommendations supported by all working group members.
CONCLUSIONS: Specific consensus recommendations are made regarding the diagnosis of anthrax, indications for vaccination, therapy for those exposed, postexposure prophylaxis, decontamination of the environment, and additional research needs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10328075     DOI: 10.1001/jama.281.18.1735

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  145 in total

1.  Early statistical detection of anthrax outbreaks by tracking over-the-counter medication sales.

Authors:  Anna Goldenberg; Galit Shmueli; Richard A Caruana; Stephen E Fienberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

2.  Biological Warfare: Implications for Antimicrobial Use.

Authors:  Ethan Rubinstein; Itzhak Levi
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.725

Review 3.  Biological warfare and bioterrorism.

Authors:  Nicholas J Beeching; David A B Dance; Alastair R O Miller; Robert C Spencer
Journal:  BMJ       Date:  2002-02-09

4.  Prophylactic treatment of anthrax with antibiotics.

Authors:  C A Hart; N J Beeching
Journal:  BMJ       Date:  2001-11-03

5.  Hospital preparedness for victims of chemical or biological terrorism.

Authors:  D C Wetter; W E Daniell; C D Treser
Journal:  Am J Public Health       Date:  2001-05       Impact factor: 9.308

6.  Pulmonary Manifestations of Bioterrorism.

Authors:  Renuka Heddurshetti; Wadchara Pumpradit; Larry I. Lutwick
Journal:  Curr Infect Dis Rep       Date:  2001-06       Impact factor: 3.725

7.  Mailborne transmission of anthrax: Modeling and implications.

Authors:  Glenn F Webb; Martin J Blaser
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

8.  Anthrax: of bison and bioterrorism.

Authors:  E Weir
Journal:  CMAJ       Date:  2000-09-05       Impact factor: 8.262

9.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

10.  Antimicrobial effects of interferon-inducible CXC chemokines against Bacillus anthracis spores and bacilli.

Authors:  Matthew A Crawford; Yinghua Zhu; Candace S Green; Marie D Burdick; Patrick Sanz; Farhang Alem; Alison D O'Brien; Borna Mehrad; Robert M Strieter; Molly A Hughes
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.